How do transurethral needle ablation of the prostate and transurethral microwave thermotherapy compare with transurethral prostatectomy?
Explore the source record for details and available documents.
Cost-Benefit Analysis↗
Biomedical subjects
Alexis E Te
Publications and source records attributed to Alexis E Te.
PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study.
OBJECTIVES: To determine, in a prospective study, the prostate-specific antigen (PSA) response to finasteride challenge in men with a serum PSA greater than 4 ng/mL who had undergone previous biopsy. Patients with a serum PSA level greater than 4 ng/mL who have undergone repeated prostate biopsy with prostate cancer (CaP) that was not detected present a diagnostic dilemma. The magnitude of PSA reduction after administration of finasteride has been well documented. In addition, doubling of the PSA value after 1 year of finasteride has been touted to be a more useful paradigm for diagnosing CaP than PSA alone. METHODS: Thirty-eight men with a baseline serum PSA level greater than 4 ng/mL and a normal digital rectal examination who had been previously biopsied a minimum of two times, with CaP not detected, were given 5 mg finasteride daily. The PSA level was measured at 6 and 12 months with repeat transrectal ultrasonography and biopsy (12 cores) performed at 1 year. Changes in prostate volume, serum PSA, PSA density, and the incidence of CaP at 1 year were assessed. RESULTS: The mean age of the group was 60.5 years (+/-7.6). For the group, the average number of previous biopsies performed was 2.9 (range 2 to 6). The baseline PSA level for the entire group was 6.32 ng/mL (+/-3.2), and the baseline prostate volume was 37.3 cm3 (+/-12.4). At 1 year, the PSA level had decreased to 3.73 ng/mL (-41.0%), and the prostate volume had decreased to 30.4 cm3 (-18.5%). In the 11 men (29%) in whom CaP was detected, the serum PSA decreased from 7.3 to 5.2 ng/mL (-28.8%) and the prostate volume decreased from 37.3 to 32.3 cm3 (-13.4%). CaP was detected in 0 of 10 men with a serum PSA decrease of 50% or higher, in 6 (32%) of 19 men with a PSA decrease between 33% and 50%, and in 5 (56%) of 9 men who had a PSA decrease of less than 33%. CONCLUSIONS: The data in this preliminary study suggest that the magnitude of change in serum PSA after 1 year of finasteride challenge may be useful in diagnosing CaP in patients with elevated PSA levels and prior negative prostate biopsy.
Biopsy, Needle↗
A modern rationale for the use of phenoxybenzamine in urinary tract disorders and other conditions.
BACKGROUND: Phenoxybenzamine (PBZ) is a nonselective, irreversible alpha-adrenergic receptor antagonist that is approved for the treatment of diaphoresis and hypertension associated with pheochromocytoma. It may also be useful in several chronic conditions whose pathogenesis is mediated or affected by alpha-adrenergic stimulation, such as lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and neurogenic bladder (eg, secondary to myelomeningocele and in sphincter dyssynergia and autonomic dysreflexia); in an adjunctive role after urogenital surgery or brachytherapy by relieving symptoms associated with increased alpha-adrenergic tone; and in the treatment of complex regional pain syndrome (CRPS) and prostatitis. However, carcinogenic concerns may have limited its potential application. OBJECTIVE: The purpose of this article is to reassess the usefulness and contemporary application of PBZ for the control of urinary tract symptoms associated with BPH and neurogenic bladder, after urogenital surgery and brachytherapy, and in certain other conditions (eg, CRPS, prostatitis). METHODS: A search of literature published from 1966 to 2002 was performed on MEDLINE using the search terms phenoxybenzamine, alpha-adrenergic blockers, benign prostatic hyperplasia, neurogenic bladder, urinary retention, and complex regional pain RESULTS: Despite concerns about possible carcinogenicity, no reports of drug-related tumors have been made since PBZ's introduction in 1953. Investigators have used PBZ in off-label trials to alleviate symptoms of a variety of conditions that cause urinary retention. In adult male patients with retention due to inguinal hernioplasty and female patients with retention caused by vaginal repair, as well as in pediatric patients with myelomeningocele, treatment with PBZ improved bladder function and, in the patients with myelomeningocele, was associated with reduced incidence of urinary tract infection. Larger tri- als of PBZ in men with BPH produced significant urinary symptom relief (P < 0.05 in 2 studies). Moreover, studies suggest that PBZ may be useful in alleviating pain due to trauma and CRPS. The most common adverse events appear to be dizziness, impotence and ejaculatory dysfunction, and nasal stuffiness. CONCLUSIONS: No drug-related tumors in humans have been reported after -50 years of clinical experience with PBZ. Clinical trials have demonstrated that it can relieve symptoms in patients with BPH and other urologic and pain-related conditions.
Adrenergic alpha-Antagonists↗
Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?
OBJECTIVE: Asian men generally have smaller prostate gland sizes than their Western counterparts. Nonetheless, the prevalence of lower urinary tract symptoms (LUTS) is similar between native Asian men and men in the Western hemisphere. The purpose of this study was to determine if the enlargement of the transition zone volume (TZV) relative to the overall prostate volume (PV) might account for the prevalence of LUTS among Korean men despite having "smaller" prostates. METHODS: Three hundred and seventy consecutive age-matched men (94 Caucasian, 94 Hispanic, 93 African-American, and 89 Korean) with LUTS were evaluated utilizing the International Prostate Symptom Score (IPSS), peak flow rate (Q(max)), serum PSA and transrectal ultrasound (TRUS). The ratio of TZV to total PV was used to determine the transition zone index (TZI). RESULTS: Mean baseline IPSS and Q(max) were significantly different (p<0.001 and p<0.03) for Korean men (19.9+/-7.6 and 11.3+/-4.2) in comparison to African-American (14.6+/-3.7, 12.6+/-4.1), Caucasian (13.4+/-4.3, 12.5+/-3.8), and Hispanic (13.9+/-3.1, 11.9+/-4.5) men. Regardless of race, TZI correlated with IPSS (r=0.31, p<0.01) and Q(max) (r=0.26, p<0.04). Mean TZI was significantly (p<0.001) higher in Korean and African-American men (0.45+/-0.08 and 0.44+/-0.05, respectively) than Caucasian and Hispanic men (0.39+/-0.03 and 0.38+/-0.02, respectively). CONCLUSIONS: Among age-matched, ethnically diverse men with moderate to severe LUTS, Korean men demonstrated more clinical symptoms and a higher ratio of transition zone enlargement relative to total prostate in comparison to Caucasian, Hispanic, and African-American men. The clinical significance of these findings remains to be determined.
Analysis of Variance↗